Cytokine Signalling Forum

Publications





October 19

Évolution des Taux Lipidiques et de l'Incidence des Événements Cardiovasculaires Après un Traitement au Tofacitinib chez les Patients Atteints de Rhumatisme Psoriasique : Une Analyse Regroupée des Études de Phase 3 et de Prolongation à Long Terme

Gladman DD, Charles-Schoeman C, McInnes IB, Veale DJ, Thiers B, Nurmohamed M, Graham D, Wang C, Jones T, Wolk R, DeMasi R.
Arthritis Care Res (Hoboken) 2019;71(10):1387–95

Serum lipid level increases at month 3 following TOF treatment in PsA were consistent with observation in RA and psoriasis. The risk of CV disease is higher in people with PsA versus the general population – comparable with the well-documented rates seen in RA and diabetes. The reasons for this are not fully elucidated, but it has been suggested that there is an association between peripheral joint inflammation and lipid dysregulation in PsA. This post hoc analysis of pooled data from ...

Mots clefs: JAK, Tofacitinib, Clinical, Safety

Traduit par: Melissa Noack